Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shai Erlich

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Child and Adolescent Psychiatric Clinics of North America|March 5, 2025
Eating Disorders in Infancy: Assessment and InterventionsMiri Keren, Shai Erlich, Liat Ashkenazi-Hoffnung
NPJ Digital Medicine|June 14, 2025
Mobile application leads to psychological improvement and correlated neuroimmune function change in subjective cognitive declineMerav Catalogna, Nira Saporta, Bar Nathansohn-Levi, et al.
Brain Communications|May 22, 2026
Neural correlates of Parkinson's improvements after combined digital-levodopa therapy: a pilot studyMerav Catalogna, Nira Saporta, Tal Tamir, et al.
Nucleic Acid Therapeutics|August 24, 2012
Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administrationJames D Thompson, Douglas J Kornbrust, Jeffrey W-D Foy, et al.
Kidney International Reports|December 23, 2017
Safety and Tolerability Study of an Intravenously Administered Small Interfering Ribonucleic Acid (siRNA) Post On-Pump Cardiothoracic Surgery in Patients at Risk of Acute Kidney InjurySegav Demirjian, Gorav Ailawadi, Martin Polinsky, et al.
Circulation|September 3, 2021
Teprasiran, a Small Interfering RNA, for the Prevention of Acute Kidney Injury in High-Risk Patients Undergoing Cardiac Surgery: A Randomized Clinical StudyMatthias Thielmann, David Corteville, Gabor Szabo, et al.
Journal of the American Society of Nephrology : JASN|May 28, 2009
siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injuryBruce A Molitoris, Pierre C Dagher, Ruben M Sandoval, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Child and Adolescent Psychiatric Clinics of North America|March 5, 2025
Eating Disorders in Infancy: Assessment and InterventionsMiri Keren, Shai Erlich, Liat Ashkenazi-Hoffnung
NPJ Digital Medicine|June 14, 2025
Mobile application leads to psychological improvement and correlated neuroimmune function change in subjective cognitive declineMerav Catalogna, Nira Saporta, Bar Nathansohn-Levi, et al.
Brain Communications|May 22, 2026
Neural correlates of Parkinson's improvements after combined digital-levodopa therapy: a pilot studyMerav Catalogna, Nira Saporta, Tal Tamir, et al.
Nucleic Acid Therapeutics|August 24, 2012
Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administrationJames D Thompson, Douglas J Kornbrust, Jeffrey W-D Foy, et al.
Kidney International Reports|December 23, 2017
Safety and Tolerability Study of an Intravenously Administered Small Interfering Ribonucleic Acid (siRNA) Post On-Pump Cardiothoracic Surgery in Patients at Risk of Acute Kidney InjurySegav Demirjian, Gorav Ailawadi, Martin Polinsky, et al.
Circulation|September 3, 2021
Teprasiran, a Small Interfering RNA, for the Prevention of Acute Kidney Injury in High-Risk Patients Undergoing Cardiac Surgery: A Randomized Clinical StudyMatthias Thielmann, David Corteville, Gabor Szabo, et al.
Journal of the American Society of Nephrology : JASN|May 28, 2009
siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injuryBruce A Molitoris, Pierre C Dagher, Ruben M Sandoval, et al.
Pageof 1